(Q35684091)

9 August 2017

1 reference

title

Induction chemotherapy and radiotherapy in locally advanced non-small cell lung cancer (English)

1 reference

9 August 2017

2

Everett E Vokes

1 reference

9 August 2017

1

Ezra E W Cohen

1 reference

9 August 2017

publication date

1 February 2004

1 reference

Hematology / Oncology Clinics of North America

9 August 2017

published in

1 reference

9 August 2017

volume

18

1 reference

9 August 2017

issue

1

1 reference

9 August 2017

page(s)

81-90

1 reference

Two cycles of cisplatin-vindesine and radiotherapy for localized nonsmall cell carcinoma of the lung (stage III). Results of a prospective trial with 149 patients

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900148-5

7 January 2021

Neoadjuvant vindesine, etoposide, and cisplatin for locally advanced non-small cell lung cancer. Final report of a phase 2 study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900148-5

7 January 2021

Mitomycin, cisplatin, and vindesine followed by radiotherapy combined with cisplatin in stage III nonsmall cell lung cancer: long-term results

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900148-5

7 January 2021

A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900148-5

7 January 2021

Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900148-5

7 January 2021

Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900148-5

7 January 2021

Induction chemotherapy plus high-dose radiotherapy versus radiotherapy alone in locally advanced unresectable non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900148-5

7 January 2021

A randomized study of high-dose split course radiotherapy preceded by high-dose chemotherapy versus high-dose radiotherapy only in locally advanced non-small-cell lung cancer. An EORTC Lung Cancer Cooperative Group trial

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900148-5

7 January 2021

Combined radiotherapy and chemotherapy versus radiotherapy alone in locally advanced epidermoid bronchogenic carcinoma. A randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900148-5

7 January 2021

Thoracic radiation therapy alone compared with combined chemoradiotherapy for locally unresectable non-small cell lung cancer. A randomized, phase III trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900148-5

7 January 2021

A phase III randomized trial of combined chemoradiotherapy versus radiotherapy alone in locally advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900148-5

7 January 2021

Chemotherapy plus radiotherapy compared with radiotherapy alone in the treatment of locally advanced, unresectable, non-small-cell lung cancer. A meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900148-5

7 January 2021

Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb nonsmall cell lung cancer. A meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900148-5

7 January 2021

Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900148-5

7 January 2021

Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900148-5

7 January 2021

Carboplatin plus paclitaxel and sequential radiation followed by consolidation carboplatin and paclitaxel in patients with previously untreated locally advanced NSCLC. A Hoosier Oncology Group (HOG) phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900148-5

7 January 2021

Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900148-5

7 January 2021

Phase II Trial of Combination Chemotherapy and Irradiation in Non-Small-Cell Lung Cancer, Radiation Therapy Oncology Group 88–04

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900148-5

7 January 2021

Induction chemotherapy followed by concurrent standard radiotherapy and daily low-dose cisplatin in locally advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900148-5

7 January 2021

Neoadjuvant etoposide, ifosfamide, and cisplatin followed by concomitant thoracic radiotherapy and continuous cisplatin infusion in stage IIIb non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900148-5

7 January 2021

Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: cancer and leukemia group B study 9431.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900148-5

7 January 2021

Dose-escalating conformal thoracic radiation therapy with induction and concurrent carboplatin/paclitaxel in unresectable stage IIIA/B nonsmall cell lung carcinoma: a modified phase I/II trial

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900148-5

7 January 2021

Radiosensitization with carboplatin for patients with unresectable stage III non-small-cell lung cancer: a phase III trial of the Cancer and Leukemia Group B and the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900148-5

7 January 2021

Consolidation Docetaxel After Concurrent Chemoradiotherapy in Stage IIIB Non–Small-Cell Lung Cancer: Phase II Southwest Oncology Group Study S9504

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900148-5

7 January 2021

Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: a Southwest Oncology Group phase II study, SWOG 9019.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900148-5

7 January 2021

Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. Adopted on May 16, 1997 by the American Society of Clinical Oncology

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900148-5

7 January 2021

Randomized study of chemotherapy/radiation therapy combinations for favorable patients with locally advanced inoperable nonsmall cell lung cancer: Radiation Therapy Oncology Group (RTOG) 92-04

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900148-5

7 January 2021

Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900148-5

7 January 2021

Phase II randomized trial of radiotherapy alone vs the sequential use of chemotherapy and radiotherapy in stage III non-small cell lung cancer. Phase II trial of chemotherapy alone in stage IV non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900148-5

7 January 2021

10.1016/S0889-8588(03)00148-5

Identifiers

DOI

1 reference

9 August 2017

1 reference